Dapagliflozin reduces the white coat effect on systolic blood pressure of patients with type 2 diabetes: a post-hoc analysis from the ADDENDA-BHS 2 trial
Open Access
- 20 December 2024
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 41 (1) , 25-29
Abstract
White coat effect (WCE) is a phenomenon linked to increased cardiovascular risk, where office blood pressure readings exceed home or ambulatory measurements. Excess weight and elevated blood pressure or glucose are associated with WCE in type 2 diabetes (T2D). This study compared dapagliflozin and glibenclamide on WCE in T2D patients under equivalent blood pressure and glucose control. This post-hoc analysis of the ADDENDA-BHS2 trial enrolled T2D patients with high cardiovascular risk, defined by stable coronary artery disease or subclinical carotid atherosclerosis. This single-center, open-label, randomized trial included 98 participants, randomized to 12 weeks of dapagliflozin or glibenclamide, in addition to metformin. Baseline blood pressure and glucose control were adjusted to maintain equivalence. This analysis focused on 85 participants with pre- and post-treatment 24-h ambulatory blood pressure data. Despite blood pressure and glucose control, WCE was present in 28% of participants at baseline. Baseline-adjusted change in WCE on systolic BP showed median changes of -8.6 and 1.7 mmHg for dapagliflozin and glibenclamide groups, respectively (p = 0.048). This effect was not observed on diastolic blood pressure. Dapagliflozin reduces WCE on systolic blood pressure compared to glibenclamide, even under equivalent blood pressure and glucose control. The trial was registered at the Clinicaltrials.gov (NCT: 02919345).Keywords
Funding Information
- AstraZeneca do Brasil Ltda (ESR-14–10627, 304257/2021-4)
- Brazilian National Research Council
This publication has 14 references indexed in Scilit:
- SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic PatientsHypertension, 2022
- White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020Hypertension, 2021
- Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trialCardiovascular Diabetology, 2021
- The Relationship Between Fasting Blood Glucose and HypertensionAmerican Journal of Hypertension, 2019
- Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trialDiabetology & Metabolic Syndrome, 2019
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2018
- Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐AnalysisJournal of the American Heart Association, 2017
- White-Coat Isolated Systolic Hypertension Is a Risk Factor for Carotid AtherosclerosisThe Journal of Clinical Hypertension, 2016
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Diabetes & Endocrinology, 2016
- Pulse pressure is more susceptible to the white coat effect than is systolic blood presureObservations from real-life ambulatory blood pressure monitoringAmerican Journal of Hypertension, 2004